Macquarie Group
MCRB icon

Macquarie Group’s Seres Therapeutics MCRB Stock Holding History

Macquarie Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-247
Closed -$3.58K – 1821
2024
Q2 		$3.58K Buy
+247
New +$4.12K ﹤0.01% 1749
2022
Q3 		– Sell
-116
Closed -$11.9K – 2279
2022
Q2 		$8K Hold
116
– – ﹤0.01% 2477
2022
Q1 		$17 Hold
116
– – ﹤0.01% 2424
2021
Q4 		$19K Hold
116
– – ﹤0.01% 2407
2021
Q3 		$16K Hold
116
– – ﹤0.01% 2488
2021
Q2 		$55K Hold
116
– – ﹤0.01% 2140
2021
Q1 		$48K Sell
116
-2,971
-96% -$1.37M ﹤0.01% 2087
2020
Q4 		$1.51M Buy
+3,087
New +$1.81M ﹤0.01% 1188
2018
Q1 		– Sell
-45
Closed -$9K – 2284
2017
Q4 		$9K Buy
+45
New +$9.24K ﹤0.01% 2278

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Macquarie Group's MCRB Position: Q3 2024 in Review

Macquarie Group sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 247 shares — an estimated $3.58K sold.

Macquarie Group first reported a position in MCRB in Q4 2017 and held it in 9 quarters. The position peaked at $1.51M in Q4 2020. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • Macquarie Group reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Macquarie Group sold 247 Seres Therapeutics shares in Q3 2024, an estimated $3.58K.
  • Macquarie Group first reported a position in Seres Therapeutics in Q4 2017 and held it in 9 quarters.
  • Macquarie Group's Seres Therapeutics position peaked at $1.51M in Q4 2020.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.